Brainstorm Cell Therapeutics (BCLI) and Erytech Pharma (ERYP) Head-To-Head Analysis

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Erytech Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Brainstorm Cell Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Erytech Pharma has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Insider & Institutional Ownership

11.6% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 14.7% of Erytech Pharma shares are owned by institutional investors. 22.6% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Brainstorm Cell Therapeutics and Erytech Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brainstorm Cell Therapeutics N/A -101.86% -59.62%
Erytech Pharma N/A N/A N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Brainstorm Cell Therapeutics and Erytech Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics 0 0 3 0 3.00
Erytech Pharma 0 0 1 0 3.00

Brainstorm Cell Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 165.96%. Given Brainstorm Cell Therapeutics’ higher possible upside, equities analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Erytech Pharma.

Earnings and Valuation

This table compares Brainstorm Cell Therapeutics and Erytech Pharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Brainstorm Cell Therapeutics N/A N/A -$4.95 million ($0.26) -14.46
Erytech Pharma N/A N/A -$37.89 million ($3.33) -2.55

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Erytech Pharma, indicating that it is currently the more affordable of the two stocks.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

About Erytech Pharma

ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply